Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms

Status Completed

Clinical Trial Summary

Detection of the potential oncogenic role of Engrailed-2 in epithelial ovarian neoplasms, in order to detect biological markers that could be targeted and blocked by new medications.

Clinical Trial Description

Epithelial ovarian carcinomas represent more than 90% of all ovarian carcinomas. Treatment of these ovarian carcinomas on basis of their histopathological features didn't improve patients' outcomes with very high incidence of relapses and resistance to therapy. Detection of novel biological markers which are involved in tumor progression could have promising results if these biological molecules are targeted and blocked by new medications. Engrailed-2 is a protein encoded by a gene located on chromosome 7. Engrailed-2 is involved in neural development and neural connections during embryological life. it has been proved that Engrailed-2 is expressed in non neural neoplasms, especially in prostatic and urinary bladder carcinomas. Now estimatiion of urinary and serum levels of Engrailed-2 is used as a non-invasive screening tool in to detect prostatic and urinary bladder carcinomas. We aim to evaluated immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues and to compare such expression between normal and neoplastic tissues in order to improve its oncogenic role in ovarian carcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05553067
Study type	Observational
Source	Sohag University
Contact
Status	Completed
Phase
Start date	January 1, 2015
Completion date	June 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03371693` - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer	Phase 3
Active, not recruiting	`NCT03648489` - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	Phase 2
Active, not recruiting	`NCT02950064` - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Phase 1
Completed	`NCT02569983` - The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research
Withdrawn	`NCT02243059` - Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer	Phase 4
Terminated	`NCT02055690` - PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer	Phase 1/Phase 2
Completed	`NCT01719926` - Phase I Platinum Based Chemotherapy Plus Indomethacin	Phase 1
Completed	`NCT00243685` - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	Phase 2/Phase 3
Completed	`NCT00415181` - Pharmacogenomics of Paclitaxel in Ovarian Cancer	N/A
Recruiting	`NCT01789229` - Establishment of a Tumor Bank for Tissue Samples
Completed	`NCT00772863` - Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer	Phase 2
Completed	`NCT00069160` - Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer	Phase 2
Completed	`NCT00046800` - Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer	Phase 2
Completed	`NCT00035100` - EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer	Phase 2
Terminated	`NCT00034372` - Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma	Phase 2
Completed	`NCT00001272` - A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients	Phase 1
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2
Recruiting	`NCT05001282` - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	Phase 1/Phase 2
Completed	`NCT02227654` - Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors	N/A
Not yet recruiting	`NCT04055038` - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)	Phase 2/Phase 3